BB Biotech (BION)

Last close As at 21/11/2024

CHF35.95

−0.05 (−0.14%)

Market capitalisation

CHF1,992m

BB Biotech, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but is managed on a bottom-up basis, with a focused c 20–35 stock portfolio.

Latest Insights

View More

Investment Companies | Flash note

BB Biotech — A key milestone with significance for the sector

Investment Companies | edison tv

BB Biotech – executive interview

Investment Companies | Update

BB Biotech — Lower rates and news flow to support recovery

Investment Companies | Flash note

BB Biotech — Positive trial news lifts two portfolio holdings

Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.

Equity Analyst

Joanne Collins

Joanne Collins

Analyst, Investment Trusts

Key Management

  • Claude Mikkelsen

    Director of IR

  • Daniel Koller

    Head of investment management

  • Dr Silvia Siegfried-Schanz

    Director of IR

  • Erich Hunziker

    Chairman

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (3.7) (10.3) (8.9)
Relative 2.8 (4.7) (15.2)
52 week high/low CHF49.4/CHF35.7

Overview

BB Biotech (BION) invests in innovative, rapidly expanding biotech companies. BION’s portfolio company Wave Life Sciences (Wave) recently announced a significant milestone in the field of genetic medicine: the first successful therapeutic RNA editing in humans. This news lifted Wave’s share price by c 60%. It follows recent positive developments in three of BION’s largest holdings, Alnylam, Intra-Cellular Therapies and Agios, which all saw substantial improvements in their longer-term revenue prospects after positive Phase III readouts. Wave’s news adds to the recent positive momentum in BION’s NAV, which rose by 5.2% in the year ended 30 September 2024, after several years of annual declines, although this return lagged the Nasdaq Biotech Index’s 12.3% rise. Yet the company’s share price declined by 8.1% over this period and the share price discount to NAV is currently over 15%, in stark contrast to an average NAV premium of c 10% over the past 10 years. With interest rates falling and the outlook for the biotech sector potentially brightening accordingly, as we argued in our August 2024 update, this may represent an opportunity for investors to acquire access to the exciting opportunities offered by this industry at what may be an uncommonly wide discount.

Research

Flash note

Investment Companies

BB Biotech — Positive trial news lifts two portfolio holdings

Review

Investment Companies

BB Biotech — A recovering sector with a healthy prognosis

Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.

Update

Investment Companies

BB Biotech — A cutting-edge sector and a high dividend

Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.

Update

Investment Companies

BB Biotech — Picking growth at good value

edison tv

Investment Companies

BB Biotech – executive interview

Review

Investment Companies

BB Biotech — Great valuation potential

edison tv

Investment Companies

BB Biotech – executive interview

Thematics

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free